Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$45.69+1.17 (+2.63%)
Close on Nov 12, 2026Market cap $853.48MP/E 3.0Yield –
Rigel Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rigel Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $79.57M, down 34.4% year over year. For fiscal 2025 it was $127.88M, up 384.0% from the year before. The highest annual figure on record is $127.88M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.88M | +384.0% |
| FY2024 | Dec 31, 2024 | $26.42M | – |
| FY2023 | Dec 31, 2023 | -$19.25M | – |
| FY2022 | Dec 31, 2022 | -$54.55M | – |
| FY2021 | Dec 31, 2021 | -$11.33M | – |
| FY2020 | Dec 31, 2020 | -$28.27M | – |
| FY2019 | Dec 31, 2019 | -$68.41M | – |
| FY2018 | Dec 31, 2018 | -$72.09M | – |
| FY2017 | Dec 31, 2017 | -$79.15M | – |
| FY2016 | Dec 31, 2016 | -$68.80M | – |
| FY2015 | Dec 31, 2015 | -$50.30M | – |
| FY2014 | Dec 31, 2014 | -$88.89M | – |
| FY2013 | Dec 31, 2013 | -$86.88M | – |
| FY2012 | Dec 31, 2012 | -$96.94M | – |
| FY2011 | Dec 31, 2011 | -$84.41M | -330.4% |
| FY2010 | Dec 31, 2010 | $36.63M | – |
| FY2009 | Dec 31, 2009 | -$110.63M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.90M | -34.9% |
| Q2 FY2026 | Jun 30, 2026 | $24.42M | -60.4% |
| Q1 FY2026 | Mar 31, 2026 | $12.48M | -6.7% |
| Q4 FY2025 | Dec 31, 2025 | $23.77M | +37.7% |
| Q3 FY2025 | Sep 30, 2025 | $29.02M | +97.9% |
| Q2 FY2025 | Jun 30, 2025 | $61.71M | +5721.7% |
| Q1 FY2025 | Mar 31, 2025 | $13.38M | – |
| Q4 FY2024 | Dec 31, 2024 | $17.26M | +664.0% |
| Q3 FY2024 | Sep 30, 2024 | $14.67M | – |
| Q2 FY2024 | Jun 30, 2024 | $1.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.57M | – |
| Q4 FY2023 | Dec 31, 2023 | $2.26M | -4.4% |
| Q3 FY2023 | Sep 30, 2023 | -$4.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.37M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.02M | -162.0% |
| Q4 FY2021 | Dec 31, 2021 | -$21.01M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.79M | – |
| Q1 FY2021 | Mar 31, 2021 | $41.99M | +98.1% |
| Q4 FY2020 | Dec 31, 2020 | -$18.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.23M | – |
| Q1 FY2020 | Mar 31, 2020 | $21.20M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.16M | -736.6% |
| Q3 FY2019 | Sep 30, 2019 | -$11.87M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.21M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.70M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.21M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.95M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.62M | – |
| Q4 FY2017 | Dec 31, 2017 | -$26.10M | – |
| Q3 FY2017 | Sep 30, 2017 | -$17.74M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.23M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.08M | – |
| Q4 FY2016 | Dec 31, 2016 | -$15.64M | – |
See a number that looks wrong?